公开(公告)号：US20230236195A1

公开(公告)日：2023-07-27

申请号：US18100076

申请日：2023-01-23

Applicant: JOINSTAR BIOMEDICAL TECHNOLOGY CO., LTD.

Inventor： Baoqing SUN ,  Nanshan ZHONG ,  Xuyi ZHOU ,  Mingshan XUE ,  Longbin HONG ,  Ming DONG

IPC: G01N33/68

CPC classification number: G01N33/68 ,  G01N2333/4703 ,  G01N2800/56

Abstract: Provided are a method for predicting a risk of deterioration of a pathogenic condition of a patient suffering a coronavirus disease (COVID-19), especially a severe patient suffering a COVID-19 and a kit thereof. The method of the present application may effectively predict the deterioration of the pathogenic condition of the patient suffering a COVID-19, thereby carrying out clinical intervention in advance, to improve prognosis of the patient suffering a COVID-19. The present application finds for the first time that the level of a heparin-binding protein (HBP) can be used as a significant indicator for early predicting relapse of the patient suffering a COVID-19, expression time of an HBP indicator is around 5 days earlier than that of a series of other clinical indicators, and thus the HBP indicator particularly has a clinical value.